Together with the cohorts described above, this project uses the infrastructure of the DPUK PET-MR Imaging network (UCL, Imperial, Cambridge, Manchester, Newcastle and Edinburgh). The study team use a new compound for PET imaging in Alzheimer’s disease - the imaging agent PI-2620 - that is in development by Life Molecular Imaging.